2. Academic Validation
  3. Recent advances of CREKA peptide-based nanoplatforms in biomedical applications

Recent advances of CREKA peptide-based nanoplatforms in biomedical applications

  • J Nanobiotechnology. 2023 Mar 3;21(1):77. doi: 10.1186/s12951-023-01827-0.
Nannan Zhang 1 2,  Bin Ru 1 2,  Jiaqi Hu 1 2,  Langhai Xu 1 2,  Quan Wan 1 2,  Wenlong Liu 1 2,  WenJun Cai 1 2,  Tingli Zhu 1 2,  Zhongwei Ji 1 2,  Ran Guo 1 2,  Lin Zhang 3,  Shun Li 4 5,  Xiangmin Tong 6
Affiliations

Affiliations

  • 1 Laboratory Medicine Center, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
  • 2 Center for Rehabilitation Medicine, Department of Pain Management, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
  • 3 College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, China. zhanglin@zju.edu.cn.
  • 4 Laboratory Medicine Center, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China. 1148449287@qq.com.
  • 5 Center for Rehabilitation Medicine, Department of Pain Management, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China. 1148449287@qq.com.
  • 6 Laboratory Medicine Center, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China. tongxiangmin@163.com.
PMID: 36869341 DOI: 10.1186/s12951-023-01827-0
Abstract

Nanomedicine technology is a rapidly developing field of research and application that uses nanoparticles as a platform to facilitate the diagnosis and treatment of diseases. Nanoparticles loaded with drugs and imaging contrast agents have already been used in clinically, but they are essentially passive delivery carriers. To make nanoparticles smarter, an important function is the ability to actively locate target tissues. It enables nanoparticles to accumulate in target tissues at higher concentrations, thereby improving therapeutic efficacy and reducing side effects. Among the different ligands, the CREKA peptide (Cys-Arg-Glu-Lys-Ala) is a desirable targeting ligand and has a good targeting ability for overexpressed fibrin in different models, such as cancers, myocardial ischemia-reperfusion, and atherosclerosis. In this review, the characteristic of the CREKA peptide and the latest reports regarding the application of CREKA-based nanoplatforms in different biological tissues are described. In addition, the existing problems and future application perspectives of CREKA-based nanoplatforms are also addressed.

Keywords

Active targeting; Biomedical applications; CREKA peptide; Fibrin-fibronectin complexes; Nanoplatform.

Figures
Products